Clinical Focus ›› 2026, Vol. 41 ›› Issue (10): 948-954.doi: 10.3969/j.issn.1004-583X.2026.10.013
Previous Articles Next Articles
-
Received:2026-09-30Online:2026-10-20Published:2026-10-10
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.10.013
| [1] | Zheng Q, Wang X. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy[J]. Protein Cell, 2025, 16(2): 83-120. doi: 10.1093/procel/pwae026. |
| [2] | Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD[J]. Eur J Nucl Med Mol Imaging, 2005, 32(4): 486-510. doi: 10.1007/s00259-005-1762-7. |
| [3] |
Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease[J]. Nat Rev Immunol, 2011, 11(11): 775-787. doi: 10.1038/nri3086.
pmid: 22025055 |
| [4] |
Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration[J]. Cell, 2010, 140(6): 918-934. doi: 10.1016/j.cell.2010.02.016.
pmid: 20303880 |
| [5] | 侯璐, 孙聪, 周晓晶, 等. 小胶质细胞代谢重编程及其在神经退行性疾病中作用的研究进展[J]. 中国实验诊断学, 2026, 30(1):123-128. |
| [6] | Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states[J]. Br J Pharmacol, 2016, 173(4): 649-665. doi: 10.1111/bph.13139. |
| [7] | Cheng J, Zhang R, Xu Z, et al. Early glycolytic reprogramming controls microglial inflammatory activation[J]. J Neuroinflammation, 2021, 18(1): 129. doi: 10.1186/s12974-021-02187-y. |
| [8] |
Johnson ECB, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation[J]. Nat Med, 2020, 26(5): 769-780. doi: 10.1038/s41591-020-0815-6.
pmid: 32284590 |
| [9] | Grüning NM, Agostini F, Caldana C, et al. The return of metabolism: Biochemistry and physiology of glycolysis[J]. Biol Rev Camb Philos Soc, 2026, 101(2): 751-803. doi: 10.1111/brv.70104. |
| [10] |
Leng L, Yuan Z, Pan R, et al. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance[J]. Nat Metab, 2022, 4(10): 1287-1305. doi: 10.1038/s42255-022-00643-4.
pmid: 36203054 |
| [11] |
Zhang Q, Wang SS, Zhang Z, et al. PKM2-mediated metabolic reprogramming of microglia in neuroinflammation[J]. Cell Death Discov, 2025, 11(1): 149. doi: 10.1038/s41420-025-02453-5.
pmid: 40189596 |
| [12] | Liu Y, Kwok W, Yoon H, et al. Imbalance in glucose metabolism regulates the transition of microglia from homeostasis to disease-associated microglia stage 1[J]. J Neurosci, 2024, 44(20):e1563232024. doi: 10.1523/JNEUROSCI.1563-23.2024. |
| [13] |
Palsson-McDermott EM, Curtis AM, Goel G, et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages[J]. Cell Metab, 2015, 21(1): 65-80. doi: 10.1016/j.cmet.2014.12.005.
pmid: 25565206 |
| [14] | Xie M, Yu Y, Kang R, et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation[J]. Nat Commun, 2016, 7(1): 13280. doi: 10.1038/ncomms13280. |
| [15] | Ros S, Schulze A. Balancing glycolytic flux: The role of 6-phosphofructo-2-kinase/fructose 2, 6-bisphosphatases in cancer metabolism[J]. Cancer Metab, 2013, 1(1): 8. doi: 10.1186/2049-3002-1-8. |
| [16] | McIntosh A, Mela V, Harty C, et al. Iron accumulation in microglia triggers a cascade of events that leads to altered metabolism and compromised function in APP/PS1 mice[J]. Brain Pathol, 2019, 29(5): 606-621. doi: 10.1111/bpa.12704. |
| [17] |
Baik SH, Kang S, Lee W, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer's disease[J]. Cell Metab, 2019, 30(3): 493-507. e6. doi: 10.1016/j.cmet.2019.06.005.
pmid: 31257151 |
| [18] | Pan RY, Ma J, Kong XX, et al. Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid-β clearance[J]. Sci Adv, 2019, 5(2): eaau6328. doi: 10.1126/sciadv.aau6328. |
| [19] | Zhang X, Alshakhshir N, Zhao L. Glycolytic metabolism, brain resilience, and Alzheimer’s disease[J]. Front Neurosci, 2021, 15: 662242. doi: 10.3389/fnins.2021.662242. |
| [20] |
TeSlaa T, Ralser M, Fan J, et al. The pentose phosphate pathway in health and disease[J]. Nat Metab, 2023, 5(8): 1275-1289. doi: 10.1038/s42255-023-00863-2.
pmid: 37612403 |
| [21] |
Stepanov YV, Golovynska I, Zhang R, et al. Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: Mechanisms of light therapy for Alzheimer's disease[J]. Alzheimers Res Ther, 2022, 14(1): 84. doi: 10.1186/s13195-022-01022-7.
pmid: 35717405 |
| [22] |
Balazs L, Leon M. Evidence of an oxidative challenge in the Alzheimer's brain[J]. Neurochem Res, 1994, 19(9): 1131-1137. doi: 10.1007/BF00965146.
pmid: 7824065 |
| [23] |
Evlice A, Ulusu NN. Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer's disease[J]. Acta Neurol Belg, 2017, 117(1): 229-234. doi: 10.1007/s13760-016-0666-6.
pmid: 27378307 |
| [24] | Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents[J]. Nat Rev Mol Cell Biol, 2020, 21(7): 363-383. doi: 10.1038/s41580-020-0230-3. |
| [25] | Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α[J]. Nature, 2013, 496(7444): 238-242. doi: 10.1038/nature11986. |
| [26] |
McGettrick AF, O’Neill LAJ. The role of HIF in immunity and inflammation[J]. Cell Metab, 2020, 32(4): 524-536. doi: 10.1016/j.cmet.2020.08.002.
pmid: 32853548 |
| [27] |
Jung ES, Choi H, Mook-Jung I. Decoding microglial immunometabolism: A new frontier in Alzheimer's disease research[J]. Mol Neurodegener, 2025, 20(1): 37. doi: 10.1186/s13024-025-00825-0.
pmid: 40149001 |
| [28] |
Yang F, Zhao D, Cheng M, et al. mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivation-induced microglial polarization for Alzheimer’s disease management[J]. ACS Nano, 2023, 17(16): 15724-15741. doi: 10.1021/acsnano.3c03232.
pmid: 37565731 |
| [29] | Liu P, Zhang T, Wu Y, et al. A peptid-drug conjugate-based nanoplatform for immunometabolic activation and in situ nerve regeneration in advanced-stage Alzheimer's disease[J]. Adv Mater, 2024, 36(46): 2408729. doi: 10.1002/adma.202408729. |
| [30] | Herzig S, Shaw RJ. AMPK: Guardian of metabolism and mitochondrial homeostasis[J]. Nat Rev Mol Cell Biol, 2018, 19(2): 121-135. doi: 10.1038/nrm.2017.95. |
| [31] | Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and energy sensor that maintains energy homeostasis[J]. Nat Rev Mol Cell Biol, 2012, 13(4): 251-262. doi: 10.1038/nrm3311. |
| [32] | Liang T, Zhang Y, Wu S, et al. The role of NLRP3 inflammasome in Alzheimer's disease and potential therapeutic targets[J]. Front Pharmacol, 2022, 13: 845185. doi: 10.3389/fphar.2022.845185. |
| [33] | Jung ES, Suh K, Han J, et al. Amyloid-β activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Syk-AMPK pathway[J]. Aging Cell, 2022, 21(5): e13623. doi: 10.1111/acel.13623. |
| [34] |
Garcia D, Shaw RJ. AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance[J]. Mol Cell, 2017, 66(6): 789-800. doi: 10.1016/j.molcel.2017.05.032.
pmid: 28622524 |
| [35] | Lin M, Yu H, Xie Q, et al. Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases[J]. Front Aging Neurosci, 2023, 14: 1100133. doi: 10.3389/fnagi.2022.1100133. |
| [36] | Wang S, Li H, Yuan M, et al. Role of AMPK in autophagy[J]. Front Physiol, 2022, 13: 1015500. doi: 10.3389/fphys.2022.1015500. |
| [37] |
Ulland TK, Song WM, Huang SCC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease[J]. Cell, 2017, 170(4): 649-663. e13. doi: 10.1016/j.cell.2017.07.023.
pmid: 28802038 |
| [38] | Hou J, Chen Y, Grajales-Reyes G, et al. TREM2 dependent and independent functions of microglia in Alzheimer’s disease[J]. Mol Neurodegener, 2022, 17(1): 84. doi: 10.1186/s13024-022-00588-y. |
| [39] | Lee S, Devanney NA, Golden LR, et al. APOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge[J]. Cell Rep, 2023, 42(3). doi: 10.1016/j.celrep.2023.112196. |
| [40] |
Millet A, Ledo JH, Tavazoie SF. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains[J]. Immunity, 2024, 57(1): 153-170. e6. doi: 10.1016/j.immuni.2023.12.001.
pmid: 38159571 |
| [41] |
Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases[J]. Immunity, 2017, 47(3): 566-581.e9. doi: 10.1016/j.immuni.2017.08.008.
pmid: 28930663 |
| [42] | Leyns CEG, Ulrich JD, Finn MB, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy[J]. Proc Natl Acad Sci U S A, 2017, 114(43): 11524-11529. doi: 10.1073/pnas.1710311114. |
| [43] | Gratuze M, Schlachetzki JCM, Albanus RDO, et al. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4[J]. Neuron, 2023, 111(2): 202-219.e7. doi: 10.1016/j.neuron.2022.10.022. |
| [44] |
Wu KC, Cui JY, Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption[J]. Toxicol Sci, 2011, 123(2): 590-600. doi: 10.1093/toxsci/kfr183.
pmid: 21775727 |
| [45] | Zgorzynska E, Dziedzic B, Walczewska A. An overview of the Nrf2/ARE pathway and its role in neurodegenerative diseases[J]. Int J Mol Sci, 2021, 22(17): 9592. doi: 10.3390/ijms22179592. |
| [46] |
Dinkova-Kostova AT, Kostov RV, Kazantsev AG. The role of Nrf2 signaling in counteracting neurodegenerative diseases[J]. FEBS J, 2018, 285(19): 3576-3590. doi: 10.1111/febs.14379.
pmid: 29323772 |
| [47] | Lee SS, Yoo YC. NOX-NOS crosstalk in the liver-brain axis: Novel insights for redox regulation and neurodegenerative diseases[J]. Redox Biol, 2025(86): 103807. doi: 10.1016/j.redox.2025.103807. |
| [48] |
Ou Z, Kong X, Sun X, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice[J]. Brain Behav Immun, 2018, 69:351-363. doi:10.1016/j.bbi.2017.12.009.
pmid: 29253574 |
| [49] | Guo S, Fu W, Wang Y, et al. Rapamycin reduces amyloid-β plaques and improves behavioral performance in a sex-dependent manner in mouse models of amyloidosis[J]. CNS Neurosci Ther, 2026, 32(3):e70807. doi:10.1002/cns.70807. |
| [1] | . [J]. Clinical Focus, 2026, 41(2): 183-187. |
| [2] | Gao Yan, Qu Shuo, Li Yang, Qiu Huiqing, He Sha, Ma Xiaowei. Interpretation of the Guidelines for the Assessment and Clinical Practice of Behavioral and Psychological Symptoms of Dementia 2025 [J]. Clinical Focus, 2025, 40(5): 389-393. |
| [3] | . [J]. Clinical Focus, 2024, 39(8): 752-757. |
| [4] | . [J]. Clinical Focus, 2023, 38(2): 185-188. |
| [5] | Sun Yanan, Hao Yifeng, Li Xiaohong. Meta analysis on diagnostic value of external anal sphincter electromyography in multiple system atrophy and Parkinson's disease [J]. Clinical Focus, 2022, 37(6): 490-496. |
| [6] | . [J]. Clinical Focus, 2015, 30(4): 446-449. |
| [7] | Zheng Lei;Zheng Wenxuan;Yuan Dongcai;Zhang Jinrong;Wei Yan. Combined detection of urinary AD7c-NTP and peripheral blood CD45RA+ T lymphocyte subsets in early diagnosis of Alzheimer disease [J]. Clinical Focus, 2015, 30(2): 196-199. |
| [8] | . [J]. CLINICAL FOCUS, 2006, 21(13): 967-0. |
| [9] | . [J]. CLINICAL FOCUS, 2005, 20(13): 752-752. |
| [10] | . [J]. CLINICAL FOCUS, 2004, 19(21): 1212-1214. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||